Integrated BioPharma Inc. (OTCMKTS:INBP – Get Free Report) shares passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.18 and traded as low as $0.1602. Integrated BioPharma shares last traded at $0.1602, with a volume of 4,000 shares traded.
Integrated BioPharma Stock Performance
The company has a market cap of $4.96 million, a PE ratio of -2.29 and a beta of 0.35. The firm’s 50 day moving average is $0.18 and its 200-day moving average is $0.25.
Integrated BioPharma (OTCMKTS:INBP – Get Free Report) last released its earnings results on Friday, May 8th. The company reported ($0.03) earnings per share for the quarter. The business had revenue of $10.11 million during the quarter. Integrated BioPharma had a negative return on equity of 8.32% and a negative net margin of 3.43%.
About Integrated BioPharma
Integrated BioPharma, Inc, together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products.
Recommended Stories
- Five stocks we like better than Integrated BioPharma
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
- Financials Hit Record Highs as the AI Trade Unravels—Can They Keep Leading?
- Netflix’s Big Sell-Off May Be Sending the Wrong Signal
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
Receive News & Ratings for Integrated BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
